Company Profile
Philogen S.p.A. is specialized in the research and development of biopharmaceuticals for the targeted treatment of cancer and chronic inflammatory diseases. In addition, the group develops technologies for the research, development and identification of targeting molecules and monoclonal antibodies. Net sales break down by source of revenue as follows:
- revenues from research, licensing and collaboration agreements (95.7%);
- revenues from research and development services (4.3%).
At the end of 2025, Philogen S.p.A. has a portfolio of 22 products in clinical development, including 3 in phase III, 12 in phase II and 8 in phase I.
Net sales are distributed geographically as follows: European Union (4.4%), the United States (95.5%) and Switzerland (0.1%).
- revenues from research, licensing and collaboration agreements (95.7%);
- revenues from research and development services (4.3%).
At the end of 2025, Philogen S.p.A. has a portfolio of 22 products in clinical development, including 3 in phase III, 12 in phase II and 8 in phase I.
Net sales are distributed geographically as follows: European Union (4.4%), the United States (95.5%) and Switzerland (0.1%).
Source: Cofisem - Last Update: 2026-05-19
Key Executives
| Chief Executive Officer | |
| Chief Scientific Officer | |
| Chief Financial Officer | |
| Chief Medical Officer | |
| Chief Human Resources Officer | |
| General Counsel | |
| Head of Investor Relations |
Source: Cofisem - Last Update: 2026-05-19
Key Figures
| Millenium | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Net sales | 314,325 | 73,996 | 23,130 | 23,713 | 2,496 |
| Income from ordinary activities | 320,121 | 77,653 | 25,121 | 27,295 | 4,964 |
| Operating income | 257,377 | 37,731 | -8,840 | 240 | -16,775 |
| Cost of financial indebtedness net | -1,018 | 89 | 155 | 406 | 403 |
| Equity-accounted companies contribution to income | |||||
| Net profit from discontinued activities | |||||
| Net income | 229,681 | 45,292 | -6,161 | -5,376 | -15,725 |
| Net income (Group share) | 229,676 | 45,292 | -6,161 | -5,376 | -15,725 |
| Fiscal year end | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Length of fiscal year (month) | 12 | 12 | 12 | 12 | 12 |
| Currency & Unit | EUR - thousands | EUR - thousands | EUR - thousands | EUR - thousands | EUR - thousands |
| Account Standards | IFRS | IFRS | IFRS | IFRS | IFRS |
Source: Cofisem - Last Update: 2026-05-19
Shareholder information
| Nerbio S.r.l. | |
| Dompè Holdings S.r.l. | |
| Free float | |
| Treasury shares |
Source: Cofisem - Last Update: 2026-05-19
Address
Philogen S.p.A.
Piazza La Lizza 7
IT-53100 Siena
Italy
Phone number: +39 0577 17816
https://www.philogen.com/investors/
Source: Cofisem - Last Update: 2026-05-19
Contact
Emanuele Puca
Phone number: +41 76 298 44 94
emanuele.puca@philogen.com
Phone number: +41 76 298 44 94
emanuele.puca@philogen.com
Source: Philogen S.p.A. - Last Update: 2026-05-19
Please contact MyQuestion.Italy@euronext.com for Company Profile support.